Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor.